NAFLD
Conditions
Brief summary
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden. The latest MRI techniques will be used to quantify the amount of hepatic fat, inflammation, liver fibrosis and body composition. Each patient will be investigated twice with three years apart to determine patients with progressive disease.
Interventions
None listed
Sponsors
Linkoeping University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diabetes type 2 * Age 35-75 year
Exclusion criteria
* Contraindication to MR * Alcohol dependance * Previously diagnosed liver cirrhosis * Previously known liver disease (other than fatty liver)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of advanced liver disease | 2020 | Number of patients with advanced liver disease (fibrosis stage \> 2) |
| The association between fitness and advanced liver disease (fibrosis >2) | 2020 | Liver fibrosis measured with MRE and liver biopsy. Fitness measured with the six minute walk test. |
| Genetic factors associated with advanced liver disease (fibrosis >2) | 2020 | Liver fibrosis measured with MRE and liver biopsy. Genes to be analyzed: PNPLA3, TM6SF2, MBOAT |
| Prevalence of fatty liver | 2020 | Number of patients with fatty liver measured with MR-PDFF |
| The association between physical activity and advanced liver disease (fibrosis >2) | 2020 | Liver fibrosis measured with MRE and liver biopsy. Physical activity measured with the international fitness scale (IFIS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients that develop symptoms of end-stage liver disease | 2030 | Symptoms of end-stage liver disease (ascites, encepahopathy, varices, HCC) or liver related Death will be recorded through chart review |
| Health economic model for disease management | 2025 | Markow model |
Countries
Sweden
Outcome results
None listed